ActX Adds COVID-19 Susceptibility Assessment to Genomic Screening

Share Article

The new information explains why a patient’s genetics suggest they are at higher or lower risk of contracting COVID-19, based on current published evidence from scholarly papers and studies.

If our inclusion of this susceptibility information can help to better inform individual patients, we will consider the project a success.

ActX’s genetic clinical decision support service, also known as GenoACT, helps physicians provide better care using the patients’ genetic data. Today, ActX announced the addition of a COVID-19 susceptibility section. This information is primarily based on blood type, as that information has been well researched thus far, but will be updated with other genes as evidence for their impact accumulates.

With ActX, once patients are genotyped or sequenced, their genetic data is stored in our secure cloud, and frequently re-analyzed based on advancing medical research. Physicians benefit from real time genetic decision support as they use their Electronic Health Record (EHR) to see patients. Patients can view their ActX results online and are notified when there is an update like the COVID-19 susceptibility data. It is important to note, for those patients whose genetics suggest their susceptibility is lower than most, the genetic impact is only moderate and proper social distancing precautions and mask use should still be observed. This is clearly outlined in the patient’s COVID-19 report.

“The service we have created with ActX helps make genomics actionable in everyday medical practice,” said Dr. Andrew Ury, founder of ActX. “We work hard to keep our service updated with the latest medical research on medications, hereditary risks, and carrier status. We are thrilled to be adding the COVID-19 information to our standard offering. I think that we’ve all seen the wide range of concerns about this virus. If our inclusion of this susceptibility information can help to better inform individual patients, we will consider the project a success. We felt that it was important to address the continuing crisis caused by the COVID-19 pandemic.”

About ActX
ActX is the industry leader in EHR-integrated precision medicine. Our service helps physicians make better decisions about medical treatment, using a patient’s genetic information to guide therapy. The ActX Genomic Service offers proven, tightly integrated, real-time genomic decision support for medication orders and actionable genomic risks, a built in patient Genomic Profile, and the ability to fully customize content.

As medications are ordered, and before the prescription is finalized, medications are checked against the patient’s genetics for efficacy, adverse reactions, and dosing. Extensive evidence based and actionable content is provided as default, customizable content, covering hundreds of genes. You can easily suppress any content or interactions, or add or modify content. The ActX Genomic Service is live at numerous U.S. health systems. For more information, visit http://www.actx.com, email info@actx.com or call 888-998-2289.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ellie Newby
ActX
+1 (888) 998-2289 Ext: 101
Email >
@ActX
since: 12/2013
Follow >
Visit website